- Home
- ZGN vs DNLI Comparison
ZGN vs DNLI Comparison
Compare ZGN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZGN | DNLI |
|---|---|---|
| Founded | 1910 | 2013 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ZGN | DNLI |
|---|---|---|
| Price | $14.40 | $23.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $11.28 | ★ $34.33 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 03-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $7.89 | $408.85 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.61 | $12.58 |
| 52 Week High | $15.44 | $27.30 |
Technical Indicators
Market Signals| Indicator | ZGN | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 45.21 |
| Support Level | $12.76 | $18.27 |
| Resistance Level | $14.52 | $23.27 |
| Average True Range (ATR) | 0.67 | 1.38 |
| MACD | 0.09 | -0.39 |
| Stochastic Oscillator | 88.69 | 17.58 |
Price Performance
Historical ComparisonAbout ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of revenue from the Zegna segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.